Georgia Erbez - 01 Jul 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2022, 16:25:41 UTC
Prior SEC filing: 01 Feb 2022
Next SEC filing: 22 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Georgia Erbez; By: Mary Christina Thomson, Attorney-In-Fact

Key filing fact

Georgia Erbez filed Form 4 for Sierra Oncology, Inc. on 01 Jul 2022.

Key facts

This page summarizes Georgia Erbez's Form 4 filing for Sierra Oncology, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2022, 16:25.

Change

Previous filing in this sequence was filed on 01 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRRA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -18,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,000
Exercise price: $17.76
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Georgia Erbez is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The options vest at the rate of 2.778% monthly, beginning on the one-month anniversary of the grant date, with 100% vested on the three-year anniversary of the grant date, subject to the provision of service by the Reporting Person to the Issuer on each vesting date.

Footnote F2

Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.